Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page now signals that it is no longer seeking participants, and adds new user-help sections (How to Read a Study Record, Common Questions, How to Join a Study) with a reformatting of the Intervention/Treatment label and an updated revision stamp from v3.5.5 to v3.6.0.
    Difference
    0.4%
    Check dated 2026-06-15T08:37:36.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.5.4 to v3.5.5, indicating a new release of the study record or page content.
    Difference
    0.0%
    Check dated 2026-06-08T04:11:59.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.4, replacing Revision: v3.5.3. This indicates a newer version of the study record.
    Difference
    0.0%
    Check dated 2026-05-17T10:07:06.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page’s displayed release/version marker was updated from “Revision: v3.5.2” to “Revision: v3.5.3” without changing the study information shown.
    Difference
    0.0%
    Check dated 2026-04-25T18:38:19.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Revision updated: v3.5.2 added; v3.5.0 removed.
    Difference
    0.0%
    Check dated 2026-04-18T13:30:26.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    Added thyroid gland undifferentiated (anaplastic) carcinoma and small cell lung carcinoma to the study's listed conditions.
    Difference
    0.1%
    Check dated 2026-03-27T23:28:57.000Z thumbnail image

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.